Key Highlights
- Net loss per share was USD 0.44, against an estimate of a USD 0.39 loss.
- Net loss widened to USD 48.08 million from USD 32.59 million.
- Research and development expenses rose to USD 43.36 million from USD 28.77 million.
- Cash and cash equivalents were USD 33.85 million at September 30, 2026.
ORIC Pharmaceuticals (NASDAQ:ORIC) reported a third quarter 2026 net loss of USD 48.08 million, compared with USD 32.59 million a year earlier. Basic and diluted net loss per share was USD 0.44, compared with USD 0.33, against an estimate of a USD 0.39 loss.
The company is a clinical-stage biopharmaceutical Business whose stated aim is to improve patients' lives by overcoming resistance in cancer. It recorded no Revenue in either period.
Research Costs Lead the Increase
Research and development expenses were USD 43.36 million, compared with USD 28.77 million, while general and administrative expenses were USD 8.19 million, compared with USD 7.90 million. Total operating expenses were USD 51.55 million, compared with USD 36.67 million, and the loss from operations was the same in both periods.
Other income, net, was USD 3.48 million, compared with USD 4.08 million. The unrealized loss on investments was USD 673 thousand, and the comprehensive loss was USD 48.75 million, compared with USD 32.16 million. Weighted average shares outstanding, basic and diluted, were 108,178,078, compared with 98,953,331.
The Nine-Month Figures
For the nine months ended September 30, 2026, Research and Development expenses were USD 111.09 million, compared with USD 83.96 million, and general and administrative expenses were USD 25.38 million, compared with USD 24.49 million. Total operating expenses were USD 136.47 million, compared with USD 108.45 million.
Other income, net, was USD 11.13 million, compared with USD 9.49 million. The net loss was USD 125.34 million, compared with USD 98.96 million, and net loss per share was USD 1.17, compared with USD 1.20. Weighted average shares outstanding were 107,230,989, compared with 82,808,969. The unrealized loss on investments was USD 2.48 million, and the comprehensive loss was USD 127.81 million, compared with USD 98.73 million.
Cash, Share Issuance and the Balance Sheet
Cash and cash equivalents were USD 33.85 million at September 30, 2026, compared with USD 45.67 million at December 31, 2025, and short-term investments were USD 227.53 million, compared with USD 235.82 million. Total Assets were USD 366.89 million, compared with USD 408.89 million. Total liabilities were USD 27.38 million, compared with USD 24.53 million, and total current liabilities were USD 24.78 million.
During the nine months, the company issued 4,698,400 shares of common stock for net proceeds of USD 59.89 million. Common stock issued and outstanding was 103,865,706 shares at September 30, 2026, compared with 98,528,949 at December 31, 2025. Stock-based compensation expense for the nine months was USD 20.18 million.
The statement of stockholders' Equity shows a net loss of USD 35.77 million for the first quarter of 2026, and the issuance of 253,847 shares on the exercise of stock Options generated USD 1.25 million.






Please wait processing your request...